Evidence map›Paper›PMID 29302829›Full record

Observational studyClinical rheumatology2018

Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.

Maria Sole Chimenti, Augusta Ortolan, Mariagrazia Lorenzin, Paola Triggianese, Marina Talamonti, Luisa Costa, Francesco Caso, Marta Favero, Miriam Teoli, Marco Galluzzo and 4 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Cycling or Swapping in Spondyloarthritis? Current Knowledge.Mediterranean journal of rheumatology · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Maria Sole ChimentiRheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
Augusta OrtolanRheumatology Unit, Department of Medicine DIMED, University of Padova, Via Giustiniani 2, 35128, Padova, Italy.
Mariagrazia LorenzinRheumatology Unit, Department of Medicine DIMED, University of Padova, Via Giustiniani 2, 35128, Padova, Italy.
Paola TriggianeseRheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
Marina TalamontiDermatology, Department of "Medicina dei Sistemi", University of Rome "Tor Vergata", Rome, Italy.
Luisa CostaRheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Francesco CasoRheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Marta FaveroRheumatology Unit, Department of Medicine DIMED, University of Padova, Via Giustiniani 2, 35128, Padova, Italy.
Miriam TeoliDermatology, Department of "Medicina dei Sistemi", University of Rome "Tor Vergata", Rome, Italy.
Marco GalluzzoDermatology, Department of "Medicina dei Sistemi", University of Rome "Tor Vergata", Rome, Italy.
Raffaele ScarpaRheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Leonardo PunziRheumatology Unit, Department of Medicine DIMED, University of Padova, Via Giustiniani 2, 35128, Padova, Italy.
Roberto PerriconeRheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
Roberta RamondaRheumatology Unit, Department of Medicine DIMED, University of Padova, Via Giustiniani 2, 35128, Padova, Italy. roberta.ramonda@unipd.it.
University of Rome Tor Vergata · ITUniversity of Padua · ITFederico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current prospective observational study aimed to evaluate the long-term (24 months), real-life effectiveness of ustekinumab in psoriatic arthritis (PsA). Consecutive patients with moderate-severe PsA and active psoriasis who begun ustekinumab treatment were evaluated prospectively (January 2015-March 2017). Clinimetric scores and biochemical values were assessed at baseline (T0), at 6 (T6), 12 (T12), and 24 (T24) months. Friedman test and generalized linear models were used to compare variables over time. Regression analysis to identify determinants of minimal disease activity (MDA) at T6 and of treatment discontinuation was conducted. Sixty-five patients (43.1% men; age 49.4 ± 11.6 years) were enrolled; ustekinumab was prescribed as a first (20%), second (33.8%), third (26.5%), fourth (15.4%), or fifth (4.6%) line biological therapy. Significant decrease in tender/swollen joints, Visual Analogue Scale of pain (VASp) and general health (VASgh), Disease Activity in PsA (DAPSA), Psoriasis Area Severity Index (PASI), Leeds Enthesitis Index (LEI), Health Assessment Questionnaire modified for spondyloarthritis (HAQ-S), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) was achieved. MDA was reached by 30.7, 47.0, and 34.0% of patients respectively at T6, T12, and T24. In multivariable models, mono-oligoarthritis was independently associated to MDA at T6 (OR 9.02; 95% CI 1.41, 57.71), while baseline CRP (OR 1.12; 95% CI 1.00, 1.26) and LEI (OR 0.50; 95% CI 0.25, 0.97) to ustekinumab discontinuation. More patients used disease-modifying antirheumatic drugs at T0 (35.3%) than at T24 (8.5%). Only nine episodes of infection and no serious adverse events were registered. In a real-life clinical setting, ustekinumab was safe and effective in PsA. Comedication tapering was often possible.

Indexed as

AdultAntirheumatic AgentsArthritis, PsoriaticFemaleHumansMaleMiddle AgedProspective StudiesRemission InductionRetreatmentSeverity of Illness IndexTreatment FailureTreatment OutcomeTumor Necrosis Factor-alphaUstekinumabAntirheumatic AgentsTumor Necrosis Factor-alphaUstekinumabBiologicalDiscontinuationMinimal disease activityPsoriatic arthritisReal-lifeUstekinumab

Identifiers

PMID29302829
OpenAlexW2782359772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.